Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 18/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6464434 | 0.86 | CTSS (0.43) | CTSSCYP3A4CYP2C9 | |
| SCHEMBL7043320 | 0.75 | CTSS (0.43) | CTSSCYP3A4CYP2C9 | |
| SCHEMBL6468407 | 0.74 | EPHX2 (0.38) | CTSSCYP3A4CYP2C9 | |
| SCHEMBL7047985 | 0.74 | CTSS (0.39) | CTSSCYP3A4CYP2C9 | |
| SCHEMBL7048391 | 0.73 | FAAH (0.40) | — | |
| SCHEMBL6467699 | 0.73 | CTSS (0.42) | CTSSCYP3A4CYP2C9 | |
| SCHEMBL6465213 | 0.72 | CTSS (0.40) | CTSSCYP3A4CYP2C9 | |
| SCHEMBL6468432 | 0.72 | GART (0.34) | CTSSCYP3A4CYP2C9HPGD | |
| SCHEMBL7049143 | 0.71 | HTT (0.34) | CTSSCYP3A4CYP2C9 | |
| SCHEMBL5517459 | 0.71 | FAAH (0.45) | CTSSCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | CTSS 9/4885CYP3A4 1183/4885CYP2C9 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.